Unknown

Dataset Information

0

Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.


ABSTRACT: To report long-term survival and toxicity outcomes with the use of high-dose intensity modulated radiation therapy (IMRT) to 86.4 Gy for patients with localized prostate cancer.Between August 1997 and December 2008, 1002 patients were treated to a dose of 86.4 Gy using a 5-7 field IMRT technique. Patients were stratified by prognostic risk group based on National Comprehensive Cancer Network risk classification criteria. A total of 587 patients (59%) were treated with neoadjuvant and concurrent androgen deprivation therapy. The median follow-up for the entire cohort was 5.5 years (range, 1-14 years).For low-, intermediate-, and high-risk groups, 7-year biochemical relapse-free survival outcomes were 98.8%, 85.6%, and 67.9%, respectively (P<.001), and distant metastasis-free survival rates were 99.4%, 94.1%, and 82.0% (P<.001), respectively. On multivariate analysis, T stage (P<.001), Gleason score (P<.001), and >50% of initial biopsy positive core (P=.001) were predictive for distant mestastases. No prostate cancer-related deaths were observed in the low-risk group. The 7-year prostate cancer-specific mortality (PCSM) rates, using competing risk analysis for intermediate- and high-risk groups, were 3.3% and 8.1%, respectively (P=.008). On multivariate analysis, Gleason score (P=.004), percentage of biopsy core positivity (P=.003), and T-stage (P=.033) were predictive for PCSM. Actuarial 7-year grade 2 or higher late gastrointestinal and genitourinary toxicities were 4.4% and 21.1%, respectively. Late grade 3 gastrointestinal and genitourinary toxicity was experienced by 7 patients (0.7%) and 22 patients (2.2%), respectively. Of the 427 men with full potency at baseline, 317 men (74%) retained sexual function at time of last follow-up.This study represents the largest cohort of patients treated with high-dose radiation to 86.4 Gy, using IMRT for localized prostate cancer, with the longest follow-up to date. Our findings indicate that this treatment results in excellent clinical outcomes with acceptable toxicity.

SUBMITTER: Spratt DE 

PROVIDER: S-EPMC5705018 | BioStudies | 2013-01-01T00:00:00Z

SECONDARY ACCESSION(S): NCT00104741

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5514232 | BioStudies
2013-01-01 | S-EPMC3840044 | BioStudies
2017-01-01 | S-EPMC5707427 | BioStudies
2016-01-01 | S-EPMC5065713 | BioStudies
2018-01-01 | S-EPMC6804854 | BioStudies
2015-01-01 | S-EPMC5002994 | BioStudies
2017-01-01 | S-EPMC5708754 | BioStudies
1000-01-01 | S-EPMC5583523 | BioStudies
2017-01-01 | S-EPMC5568111 | BioStudies
2018-01-01 | S-EPMC6615042 | BioStudies